Indivior PLC (NASDAQ:INDV) Shares Sold by Artemis Investment Management LLP

Artemis Investment Management LLP lessened its position in Indivior PLC (NASDAQ:INDV) by 83.8% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 160,000 shares of the company’s stock after selling 824,681 shares during the period. Artemis Investment Management LLP’s holdings in Indivior were worth $2,509,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of INDV. FourWorld Capital Management LLC purchased a new stake in Indivior in the first quarter valued at approximately $2,215,000. Janus Henderson Group PLC grew its stake in shares of Indivior by 14.2% during the 1st quarter. Janus Henderson Group PLC now owns 440,121 shares of the company’s stock valued at $9,424,000 after buying an additional 54,750 shares during the period. Quadrature Capital Ltd acquired a new stake in shares of Indivior during the 1st quarter worth $1,523,000. Toronto Dominion Bank boosted its holdings in Indivior by 58.0% in the first quarter. Toronto Dominion Bank now owns 2,094,865 shares of the company’s stock valued at $44,872,000 after acquiring an additional 769,000 shares during the last quarter. Finally, M&G Plc acquired a new position in Indivior in the first quarter valued at $2,518,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on INDV. Piper Sandler started coverage on shares of Indivior in a research note on Tuesday, July 23rd. They set an “overweight” rating and a $22.00 price objective on the stock. Craig Hallum cut their price objective on shares of Indivior from $37.00 to $24.00 and set a “buy” rating on the stock in a report on Wednesday, July 10th.

Indivior Stock Performance

Shares of NASDAQ:INDV traded down $0.36 during trading on Monday, hitting $12.24. 166,311 shares of the company traded hands, compared to its average volume of 258,749. The company has a quick ratio of 0.68, a current ratio of 0.85 and a debt-to-equity ratio of 23.50. The business’s fifty day moving average is $14.25 and its 200-day moving average is $17.45. The stock has a market capitalization of $1.69 billion, a price-to-earnings ratio of 1,252.00 and a beta of 0.69. Indivior PLC has a one year low of $9.14 and a one year high of $23.89.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.